I-scan With Magnification for the Detection of Gastric Intestinal Metaplasia
Primary Purpose
Gastric Intestinal Metaplasia
Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
I-scan with magnification
Standard endoscopy
Sponsored by
About this trial
This is an interventional diagnostic trial for Gastric Intestinal Metaplasia
Eligibility Criteria
Inclusion Criteria:
- patients with dyspeptic symptoms and aged 40 years or older
- or patients with Helicobacter pylori infection, or histologically verified gastric intestinal metaplasia or atrophic gastritis
- or patients with family history of gastric cancer
Exclusion Criteria:
- presence of gastrectomy, acute gastrointestinal bleeding, or known gastric neoplasia
- presence of conditions unsuitable for endoscopy procedure including coagulopathy, impaired cardiopulmonary function , pregnancy or breastfeeding
- inability to provide informed consent
Sites / Locations
- Department of Gastroenterology, Qilu Hospital, Shandong UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Group 1
Group 2
Arm Description
I-scan with magnification targeted biopsies for gastric intestinal metapalsia.
Standard endoscopy with a standard biopsy protocol from the five standard biopsy sites following the updated Sydney System including two from the distal antrum (within 2-3cm from the pylorus, greater/lesser curvature), one from the incisura and two from the mid corpus (greater/lesser curvature).
Outcomes
Primary Outcome Measures
Difference of the detection rate of gastric intestinal metaplasia between i-scan with magnification targeted biopsies and standard endoscopy with standard biopsy protocol in a per-pateint analysis
Difference of the detection rate of gastric intestinal metaplasia between i-scan with magnification targeted biopsies and standard endoscopy with standard biopsy protocol in a per-biopsy analysis
Secondary Outcome Measures
Number of biopsies needed in per group
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02516735
Brief Title
I-scan With Magnification for the Detection of Gastric Intestinal Metaplasia
Official Title
I-scan With Magnification Targeted Biopsies Compared With a Standard Biopsy Protocol for the Detection of Gastric Intestinal Metaplasia in a High Risk Population: a Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
August 2015
Overall Recruitment Status
Unknown status
Study Start Date
May 2015 (undefined)
Primary Completion Date
November 2015 (Anticipated)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Shandong University
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to assess whether i-scan with magnification can reduce the biopsy number needed per patient for the detection of gastric intestinal metaplasia without the loss of corresponding diagnostic yield.
Detailed Description
Gastric intestinal metaplasia is regarded as an important premalignant lesion for intestinal type gastric cancer. Currently, the histological assessment of gastric intestinal metaplasia still relies on the biopsies took from five sites that the updated Sydney System recommended. However, the updated Sydney System biopsy protocol needs more biopsy number and procedure time, for it is unable to satisfy the diagnosis of gastric intestinal metaplasia. I-scan is a novel image-enhanced endoscopy system based on the post processing of reflected light without optical filters. Targeted biopsy protocol based on i-scan with magnification will be possible for the diagnosis of gastric intestinal metaplasia. This study aims to compare the diagnostic yield of gastric intestinal metaplasia from i-scan with magnification targeted biopsies and a standard biopsy protocol and assess whether i-scan with magnification can reduce the biopsy number needed per patient for the detection of gastric intestinal metaplasia without the loss of corresponding diagnostic yield.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastric Intestinal Metaplasia
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
164 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Group 1
Arm Type
Experimental
Arm Description
I-scan with magnification targeted biopsies for gastric intestinal metapalsia.
Arm Title
Group 2
Arm Type
Active Comparator
Arm Description
Standard endoscopy with a standard biopsy protocol from the five standard biopsy sites following the updated Sydney System including two from the distal antrum (within 2-3cm from the pylorus, greater/lesser curvature), one from the incisura and two from the mid corpus (greater/lesser curvature).
Intervention Type
Device
Intervention Name(s)
I-scan with magnification
Intervention Type
Device
Intervention Name(s)
Standard endoscopy
Primary Outcome Measure Information:
Title
Difference of the detection rate of gastric intestinal metaplasia between i-scan with magnification targeted biopsies and standard endoscopy with standard biopsy protocol in a per-pateint analysis
Time Frame
seven months
Title
Difference of the detection rate of gastric intestinal metaplasia between i-scan with magnification targeted biopsies and standard endoscopy with standard biopsy protocol in a per-biopsy analysis
Time Frame
seven months
Secondary Outcome Measure Information:
Title
Number of biopsies needed in per group
Time Frame
seven months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
patients with dyspeptic symptoms and aged 40 years or older
or patients with Helicobacter pylori infection, or histologically verified gastric intestinal metaplasia or atrophic gastritis
or patients with family history of gastric cancer
Exclusion Criteria:
presence of gastrectomy, acute gastrointestinal bleeding, or known gastric neoplasia
presence of conditions unsuitable for endoscopy procedure including coagulopathy, impaired cardiopulmonary function , pregnancy or breastfeeding
inability to provide informed consent
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yanqing Li, PhD. MD.
Phone
18678827666
Ext
82169508
Email
qiluliyanqing@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yanqing Li, PhD. MD.
Organizational Affiliation
Department of Gastroenterology, Qilu Hospital, Shandong University
Official's Role
Study Director
Facility Information:
Facility Name
Department of Gastroenterology, Qilu Hospital, Shandong University
City
Jinan
State/Province
Shandong
ZIP/Postal Code
250012
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yanqing Li, PhD. MD.
Phone
18678827666
Ext
82169508
Email
qiluliyanqing@gmail.com
12. IPD Sharing Statement
Learn more about this trial
I-scan With Magnification for the Detection of Gastric Intestinal Metaplasia
We'll reach out to this number within 24 hrs